Dual silencing of integrin αvβ3 receptor and insulin-like growth factor 1 receptor using mPEG-PCL/DDAB hybrid nanoparticle loaded siRNA in breast cancer therapy: An in vitro study on MCF-7 cells

Detailed Discussion & Nanotech Implementation

This study addresses a key limitation of single-target gene silencing in breast cancer: tumor cells can often compensate when only one growth-signaling pathway is blocked. By co-encapsulating siRNA against both integrin αvβ3 and IGF-1R within a single mPEG-PCL/DDAB hybrid nanoparticle, the formulation was designed to interrupt two receptors implicated in MCF-7 breast cancer cell proliferation and survival at once. The cationic lipid component (DDAB) supports siRNA complexation and cellular uptake, while the mPEG-PCL polymer shell contributes to nanoparticle stability. The in vitro work on MCF-7 cells builds directly on the earlier IGF-1R-only silencing system (2022, below), extending it to dual-target silencing.